Gain Therapeutics Inc (GANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.62 Million) by net assets ($18.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Gain Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Gain Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Gain Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Gain Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gain Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emami Paper Mills Limited
NSE:EMAMIPAP
|
0.211x |
|
Lee Feed Mill Public Company Limited
BK:LEE
|
0.019x |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
-0.083x |
|
Actic Group AB
ST:ATIC
|
0.198x |
|
Anfield Energy Inc.
NASDAQ:AEC
|
-0.070x |
|
Fortune Information Systems Corp
TW:2468
|
0.088x |
|
Ares International Corp
TW:2471
|
0.142x |
|
Eaton Vance California MIT
NYSE MKT:CEV
|
0.018x |
Annual Cash Flow Conversion Efficiency for Gain Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Gain Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see GANX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.56 Million | $-18.47 Million | -0.995x | +61.32% |
| 2024-12-31 | $7.34 Million | $-18.87 Million | -2.572x | -71.45% |
| 2023-12-31 | $12.58 Million | $-18.87 Million | -1.500x | -92.74% |
| 2022-12-31 | $18.88 Million | $-14.69 Million | -0.778x | -119.12% |
| 2021-12-31 | $34.82 Million | $-12.37 Million | -0.355x | +32.02% |
| 2020-12-31 | $6.20 Million | $-3.24 Million | -0.522x | -112.58% |
| 2019-12-31 | $-449.86K | $-1.87 Million | 4.154x | +430.50% |
| 2018-12-31 | $-950.91K | $-744.51K | 0.783x | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more